United Therapeutics Corp (NASDAQ:UTHR) Chairperson and CEO Martine A. Rothblatt has reported significant insider trading activity involving the exercise of stock options and the subsequent sale of company common stock. On April 21, 2026, these transactions resulted in a total value of approximately $5.42 million.
The transaction sequence began with the acquisition of 9,500 shares of United Therapeutics common stock through the exercise of existing stock options. These options were exercised at a price of $146.03 per share, representing a total cost of $1,387,285. Immediately following this acquisition, Rothblatt disposed of the 9,500 shares. The sale prices for these shares ranged from $564.3545 to $575.7155 per share, bringing the aggregate value of the sales to $5,419,006.
Strategic Trading Framework
Both the acquisition of the shares via option exercise and the subsequent sale of common stock were carried out under a Rule 10b5-1 trading plan. This specific regulatory framework was adopted by Rothblatt on November 7, 2025. The established plan is scheduled to remain in effect until December 31, 2026, or until a total of 1,734,410 stock options (which carry an expiration date of March 17, 2027) have been exercised, whichever event occurs first.
Market Context and Valuation
The timing of these transactions coincides with a period of notable performance for United Therapeutics. The company's stock is currently trading near its 52-week high of $607.89, following a 96% increase in share value over the past year. As of the reporting period, United Therapeutics maintains a market capitalization of $25.07 billion. However, valuation metrics present a complex picture; analysis from InvestingPro suggests the stock may be overvalued relative to its Fair Value estimate, categorizing it among companies on the Most Overvalued list.
Current Ownership Structure
Following the execution of these trades, Rothblatt's direct holdings in United Therapeutics common stock stand at 40,513 shares. The CEO also maintains various forms of indirect ownership through several vehicles:
- 166 shares held by a spouse.
- 324,443 shares held in family trusts where investment power is shared among family members who are beneficiaries.
- 258,117 shares held in family trusts where the spouse serves as the sole trustee/beneficiary or as a co-trustee/settlor with power to revoke.
- 45,596 shares held in family trusts where investment power is shared with a spouse and family members are beneficiaries.
- 10,962 shares held in family trusts where Rothblatt serves as the sole trustee/beneficiary or as a co-trustee/settlor with power to revoke.
Clinical and Research Developments
Beyond insider transactions, United Therapeutics has reached several clinical milestones. The U.S. Food and Drug Administration (FDA) recently granted Regenerative Medicine Advanced Therapy designation to miroliverELAP. This investigational device for liver support was developed by Miromatrix Medical Inc. and is designed to provide temporary assistance to patients suffering from acute liver failure.
Furthermore, the company is preparing for a significant presence at the International Society for Heart and Lung Transplantation Annual Meeting. United Therapeutics intends to deliver 11 data presentations during this event, focusing on research findings from the ARTISAN studies regarding arterial hypertension and the PHINDER studies concerning pulmonary hypertension.
Analyst Outlook
Wall Street analysts have expressed varying degrees of optimism regarding the company's trajectory. Raymond James initiated coverage with an Outperform rating and set a price target of $700, pointing toward potential peak sales for Tyvaso in cases of idiopathic pulmonary fibrosis. H.C. Wainwright also maintained a Buy rating while raising its price target to $660, citing data from the TETON-1 trial for Tyvaso. Additionally, BofA Securities increased its price target to $626, following positive results from Phase 3 trials for the same medication. These assessments highlight an industry-wide focus on United Therapeutics' potential within the idiopathic pulmonary fibrosis market.